Analyst Price Target is $7.90
▲ +37.15% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Ocugen in the last 3 months. The average price target is $7.90, with a high forecast of $15.00 and a low forecast of $4.00. The average price target represents a 37.15% upside from the last price of $5.76.
Current Consensus is
The current consensus among 5 polled investment analysts is to hold stock in Ocugen. This rating has held steady since September 2020, when it changed from a Buy consensus rating.
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.